Case Studies
Anonymized examples showing how our analysis identifies risks that standard due diligence misses.
Historical Analysis
Retrospective Analysis: We applied our framework to documented public outcomes — the same patterns we identify in retrospect are what we screen for in real-time.
Each pattern we identify strengthens our proprietary database. These retrospective analyses validate the same framework we apply in real-time assessments.
Diagnostics | 2003-2018 | $700M+ raised
Elizabeth Holmes promised blood tests from a finger prick that could detect hundreds of conditions. Investors including Rupert Murdoch, the Walton family, and major VCs poured in over $700 million, valuing the company at $9 billion. The technology never worked. Holmes was convicted of wire fraud in 2022 and sentenced to 11+ years in prison.
Investors relied on charisma over evidence. A basic technical review would have revealed that running 200+ tests from microliters of blood violated fundamental physics and chemistry. No accredited lab validated the results. The defense at trial even argued that investors failed to conduct adequate due diligence.
A wound care device company achieved FDA clearance and early commercial success, then hit a wall. Payers refused coverage beyond initial pilot programs. Five years post-launch, revenue plateaued at 15% of projections.
Implantable neurostimulator cleared via 510(k) faced Class I recall within 18 months. Contract manufacturer quality issues led to $45M write-down. Company sold at distressed valuation.
Orthopedic startup built entire regulatory strategy around a single predicate device. That predicate received an FDA warning letter and was withdrawn from market. Company spent 3 years and $12M pivoting to De Novo pathway.
AI-powered diagnostic achieved FDA clearance but couldn't gain adoption. Physicians questioned clinical utility. Series C raised at 60% discount when clinical evidence gaps became apparent.
Our clinical review of a surgical navigation system identified an off-label use case with 3x market potential. Company pivoted indication strategy, achieved clearance in 11 months, acquired by strategic at premium valuation.
VC client considering $15M Series B in cardiac monitoring company. Our review identified fundamental IP weakness—core technology infringed granted patent. Client passed. Company sued 14 months later, eventually settled for $8M.
75% of medical device startups fail. Most failures stem from predictable issues: regulatory miscalculation, reimbursement assumptions, clinical evidence gaps, and manufacturing risks. Our methodology catches these patterns before they become expensive lessons.
Assessment in Action
Not every assessment uncovers fatal flaws. Sometimes we help founders fill critical gaps before they become dealbreakers.
Framework Validation
How our proprietary framework would have flagged the risks that ultimately derailed a promising medical device — using publicly available outcome data.
Transparency note: This is a retrospective analysis — not a paid engagement. We applied our framework to a real company's publicly documented trajectory to demonstrate what the assessment would have caught. Company details anonymized.
In the Headlines
Recent high-profile failures and growth misses mapped to the Vantage Score framework. Each company's setback traces back to risks our proprietary assessment is designed to catch.
Orthopedic Implants · TPG Portfolio
Defective packaging caused oxidation in implants. Recalls expanded across product lines over 3 years, triggering 2,600+ lawsuits and bankruptcy.
Maps to Vantage Framework:
Digital Therapeutics · SPAC at $1.6B
FDA-cleared prescription digital therapeutics. Assumed clearance meant payer coverage. Payers refused reimbursement at $300+/therapy. Sold for $6M in bankruptcy.
Maps to Vantage Framework:
Smart Baby Monitor · SPAC at $2.6B
Marketed pulse oximetry as consumer device without FDA clearance. FDA enforcement letter 3 months post-IPO destroyed the business model overnight.
Maps to Vantage Framework:
Handheld Ultrasound · Stock near $1-2
Revolutionary hardware, but only ~15% of exams properly billed. Workflow friction — not device quality — is the adoption bottleneck. Revenue consistently misses targets.
Maps to Vantage Framework:
VR Surgical Robotics · 87% Decline
Promised first human surgery "next year" since 2022. Still pre-revenue with $24M cash against $35M annual burn. NYSE compliance warning issued.
Maps to Vantage Framework:
Aquablation · Revenue Growing, Stock Falling
57% revenue growth wasn't enough. Saline shortage cost ~2,000 procedures (single-source risk). Market penetration at only ~10% — far slower than projected.
Maps to Vantage Framework:
If a stalled device company in your portfolio looks like any of these case studies, our Investment Forensics service can identify exactly where things went wrong — and whether they're fixable.
Founder's Corner
Founders of stalled or failed medical device companies share their stories. We analyze each through our proprietary framework — identifying the specific failure patterns and what could have been caught earlier.
Our Case Study ApproachOur case studies are built from documented medical device outcomes — real companies, real failures, real lessons. As prospective engagements join our retrospective analysis, the platform becomes the most comprehensive risk intelligence resource in medtech.
A surgical instrument startup spent 14 months on a 510(k) submission before discovering their predicate device had been reclassified. $1.8M burned on a pathway that no longer existed.
Category Tag
Regulatory Pathway (A2)Status
Could have been caught at Week 2
An AI-powered diagnostic tool cleared FDA in 11 months — then sat unused. The device added 12 minutes to a procedure physicians complete in 8. No one changed their workflow.
Category Tag
Clinical Adoption (A4)Status
Matches historical precedents in our database
A digital therapeutic achieved strong clinical outcomes and FDA clearance. Payers refused coverage at the company's price point. Revenue never exceeded 15% of projections.
Category Tag
Reimbursement Strategy (C13)Status
Matches historical precedent in our database
Have a story to share? We'll analyze it through our proprietary framework — free, confidential, and published only with your permission.
Our methodology catches these issues before they become expensive lessons.
Schedule Assessment